ReviewThe Journal of clinical and aesthetic dermatology2026
Plant-Derived Extracellular Vesicles in Dermatology: A Review of Emerging Therapeutic Applications.
Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Histopathology-Paired Clinical Improvement Following TopicalPharmaceuticals (Basel, Switzerland) · 2026Article
- Plant-Derived Nanocarriers for Drug Delivery: A Unified Framework Integrating Extracellular Vesicles, Engineered Phytocarriers, Hybrid Platforms, and Bioinspired Systems.Plants (Basel, Switzerland) · 2026Review
- Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors.Frontiers in immunology · 2026Review
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
- Therapeutic Efficacy of Plant-Derived Exosomes for Advanced Scar Treatment: Quantitative Analysis Using Standardized Assessment Scales.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exosome-Based Therapy for Skin Complications in Oncology Patients Treated with EGFR Inhibitors: A Case Report Highlighting the Need for Coordinated Dermato-Oncologic Care.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Application of StandardizedPharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis article aims to evaluate and discuss the therapeutic potential of plant-derived extracellular vesicles (PEVs) in clinical and aesthetic dermatology by examining their mechanisms, clinical application, efficacy, and safety profiles.
methodsA comprehensive literature search was completed using the keywords "plant-derived exosomes," "dermatology," "skin disorders," "treatment," "inflammatory skin conditions," "cosmetic," "regenerative medicine," "wound healing," and "chemotherapeutic skin-related toxicities." The authors reviewed all studies and included those that addressed PEVs.
resultsPEVs demonstrate multifaceted therapeutic properties: (1) immunomodulation through suppression of proinflammatory cytokines (interleukin 17, tumor necrosis factor-α), (2) restoration of skin barrier function, (3) promotion of tissue regeneration in wounds and scars, and (4) effective stabilization and delivery of therapeutic cargo (microRNAs, hydrophobic drugs). Clinical case studies, particularly with rose stem cell exosomes, show efficacy in atopic dermatitis, psoriasis, wound healing, and chemotherapy-induced dermatologic toxicities, with rapid symptom relief and structural improvement. LIMITATIONS: Current evidence is constrained by predominance of preclinical data focused primarily on mammalian-derived exosomes as well as variability in PEV isolation and characterization methods across studies. Clinical data regarding the use of PEVs remains limited in the literature.
conclusionPEVs represent a promising new class of dermatologic therapeutics combining plant-derived biocompatibility with targeted therapeutic effects. Future research should prioritize controlled clinical trials, standardization of production methods, and exploration of engineered PEVs for precision medicine applications in dermatology.
Indexed as
Identifiers
41890780PMC13016450What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.